The AeroForm System (a patient-controlled tissue expansion system utilizing CO 2 inflation) was evaluated in patients undergoing immediate or delayed breast reconstruction following mastectomy. The primary endpoint was expansion to and maintenance of clinically desired breast volume until permanent implant placement or 6 months unless prohibited by a nondevice-related failure.
Results: Forty women (mean age: 45 ± 8.4 years; mean BMI: 24 ± 3.7) enrolled in the study: 26 had a breast cancer history and 14 sought prophylactic treatment. Nine subjects had unilateral placement (22%) and 31 subjects had bilateral placement (78%) for a total of 71 tissue expanders. All 71 expanders were expanded to and maintained clinically desired breast volume until permanent implant placement. Mean time to desired expansion was 17 ± 5 days; mean time from implant of expander to permanent implant exchange was 92 ± 22 days. No device-related adverse events were reported. Thirty-three of the subjects did not complain of pain post-procedure. Of the seven subjects reporting pain (7/40, 17.5%), six described their pain as mild-to-moderate and one subject (1/40, 2.5%) described her pain as severe. Thirty-one subjects found the device very easy to use and all 32 respondents were satisfied with the results (Figures 1 and 2) . The surgeon was satisfied with the use of the device and with the ease of the explant procedure. 
Conclusions:
The patient-activated and controlled expansion system provided gentle dosing for study subjects and provided the foundation for successful and timely placement of permanent implants.
